Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 745 across all filing types
Latest filing 2011-01-03 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science : Recrutement du premier patient dans l’étude de phase 3 dans le mélanome métastatique
Regulatory Filings Classification · 95% confidence The document is a press release dated January 3, 2011, announcing that AB Science has recruited the first patient in a Phase 3 study comparing masitinib to dacarbazine for metastatic melanoma with a specific c-Kit mutation. It details the study design, the scientific rationale, and the company's pipeline. This content is characteristic of an announcement regarding clinical trial progress and drug development, which falls under general corporate or investor news. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), and it is not a presentation (IP) or a transcript (CT), the most appropriate classification is 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'LTR' if viewed as an update on a significant ongoing legal/regulatory process related to drug development, but RNS is the best fit for a general press release about clinical trial milestones that doesn't fit a more specific category like DIV, DIRS, or MANG. Given the context of a clinical trial update press release, RNS (Regulatory Filings/General Announcement) is the standard fallback for non-standard, yet important, corporate news.
2011-01-03 French
AB SCIENCE: Publication of Long-Term Survival of Dogs with Mast Cell Tumours Treated with Masitinib
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science SA regarding the publication of long-term survival data for their drug masitinib in treating canine mast cell tumors. The text details the findings, quotes the CEO, and provides a list of related scientific publications. This content is characteristic of a press release or news update focused on research results and scientific validation, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is an announcement detailing research findings and publications, it fits best under the general category of Investor Relations or Regulatory Filings. Given the specific nature of the content (scientific publication announcement), and lacking keywords for other specific types (like DEF 14A, DIV, CT), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release announcing a publication, RNS is the most suitable fallback for non-standard announcements.
2011-01-03 English
AB Science: Publication des données de survie à long terme de chiens traités avec le masitinib dans le mastocytome
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science SA announcing the publication of long-term survival data for dogs treated with masitinib for mast cell tumors. The text details the findings, references the publishing journal (American Journal of Veterinary Research), mentions regulatory approvals (EMA, FDA), and includes a quote from the President. Crucially, it concludes with a detailed table listing various scientific publications related to masitinib. This structure—announcing new data/publication and summarizing related research—is characteristic of a general corporate or regulatory announcement, but it is not a full financial report (10-K, IR), a proxy statement (DEF 14A), or a transcript (CT). Since it is announcing the publication of scientific results and providing context, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format announcing a publication, RNS is the most appropriate general category for non-standard, non-financial regulatory/scientific updates that don't fit elsewhere. It is not a Report Publication Announcement (RPA) because it contains substantial original content and analysis, not just a notice that a report is available.
2011-01-03 French
AB Science authorised to commercialise masitinib in the USA for treatment in canine mast cell tumor
Regulatory Filings Classification · 95% confidence The document is a press release dated December 16, 2010, announcing that AB Science received conditional approval from the US FDA for its drug masitinib for treating canine mast cell tumors. This is a specific, material business event announcement concerning regulatory approval and market entry in a specific jurisdiction (USA). It is not a comprehensive annual report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). It is a significant regulatory/business update that doesn't fit the specific categories like Director's Dealing (DIRS), M&A (TAR), or Dividend (DIV). Since it is a specific announcement of a regulatory outcome impacting the business, and it is not a general regulatory filing fallback (RNS), the most appropriate category is a general business/regulatory update. Given the options, this type of specific, material business news announcement, especially one concerning regulatory milestones, often falls under the general 'Regulatory Filings' (RNS) if a more specific category like 'Legal Proceedings Report' (LTR) or 'Capital Update' (CAP) is not applicable. However, since it is a specific announcement of a major business development (FDA approval), and not a general regulatory filing, it is best classified as a general announcement that doesn't fit the highly specific financial reporting codes. RNS is the designated fallback for miscellaneous regulatory announcements. Given the context of a press release detailing a major business/regulatory milestone, RNS is the most suitable general regulatory announcement category available.
2010-12-16 English
AB Science : Informations relatives au nombre total de droits de vote et d’actions
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and explicitly references regulations from the Autorité des Marchés Financiers (AMF). It provides a snapshot of the total voting rights and shares as of a specific date (November 30, 2010). This type of mandatory disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific announcement related to capital/share structure. Given the options, it most closely aligns with a notification about the capital structure or a general regulatory filing. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory disclosure, it fits best under 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, since it is a periodic disclosure of existing shares/rights rather than an issuance or change event, RNS is the most appropriate general regulatory category for mandatory disclosures not covered elsewhere. The document length is short (2295 chars), but it is the primary content, not an announcement of another report, so the RPA rule does not strictly apply here to downgrade it further.
2010-12-03 French
Ab Science : Calendrier financier 2011
Report Publication Announcement Classification · 99% confidence The document is dated November 29, 2010, and its primary content is a table titled "Calendrier de communication financière 2011" (2011 Financial Communication Calendar). This calendar lists future dates for key corporate events such as revenue releases, earnings presentations, interim financial information, and the Annual General Meeting (AGM). Since the document itself is an announcement detailing *when* future reports and meetings will occur, rather than being one of those reports (like an ER, IR, or 10-K), it fits best under the category for announcing the publication or schedule of reports. The most appropriate code for an announcement regarding the timing/schedule of future corporate reports is Report Publication Announcement (RPA). The document length (2386 chars) is short, supporting the idea that it is an announcement rather than a full report.
2010-11-29 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.